Beta Bionics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-06. It has amended it 3 times. It filed its final prospectus on 2025-01-31, at a public offering price of $17.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Market (Nasdaq) under the symbol BBNX.From the 424B4 filed 2025-01-31
Shares offered
This is the initial public offering of shares of common stock of Beta Bionics, Inc. We are selling 12,000,000 shares of our common stock, and the underwriters have an option for a period of 30 days to purchase up to an additional 1,800,000 shares, consisting of 475,000 shares from us and 1,325,000 shares from the selling stockholders identified in this prospectus, in each case at the initial public offering price less the underwriting discounts and commissions.From the 424B4 filed 2025-01-31
Offering price
Gives effect to (i) the pro forma adjustments set forth in footnote (1) above and (ii) our sale of 12,000,000 shares of common stock in this offering and 1,000,000 shares in the concurrent private placement, at the initial public offering price of $17.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.From the 424B4 filed 2025-01-31
Use of proceeds
We intend to use the net proceeds from this offering and concurrent private placement, together with our existing cash, cash equivalents and short-term investments, to fund (i) the development of the bihormonal configuration of the iLet through regulatory submissions to the FDA for 510(k) clearance of the bihormonal configuration and for approval of the glucagon product;From the 424B4 filed 2025-01-31
Revenue
Our revenue for the nine months ended September 30, 2024 was $44.7 million, more than 3.5x that of our annual revenue of $12.0 million for the year ended December 31, 2023.From the S-1/A filed 2025-01-28
Net loss or income
Our net losses were $25.3 million for the nine months ended September 30, 2023 and $36.6 million for the nine months ended September 30, 2024.From the S-1/A filed 2025-01-28
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-06 | Registration statement filed | S-1 |
| 2025-01-22 | Registration statement amended | S-1/A |
| 2025-01-23 | Registration statement amended | S-1/A |
| 2025-01-28 | Registration statement amended | S-1/A |
| 2025-01-31 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Beta Bionics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.